OncoTarget
New York, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $280M
Overview
Developing targeted small molecule and biologic therapies for oncology with high tumor selectivity.
Oncology
Technology Platform
Integrated computational biology and medicinal chemistry platform for designing selective kinase inhibitors and engineered antibody therapeutics.
Funding History
1Total raised:$280M
Private Equity$280M
Opportunities
Potential for high-value partnerships or acquisition if lead candidate demonstrates strong proof-of-concept data in a biomarker-defined cancer population.
Risk Factors
Clinical failure of its lead Phase 2 candidate, which constitutes most of its near-term value, poses a significant existential risk.
Competitive Landscape
Operates in the highly competitive targeted oncology space, facing competition from both large pharmaceutical companies and numerous biotech startups.